º»¹® ¹Ù·Î°¡±â

·Î±×ÀÎ ¹Ù·Î°¡±â


(ÁÖ)À̸ÅÁø ±â¾÷Á¤º¸

(ÁÖ)À̸ÅÁø
  • ¹ÙÀÌ¿ÀÄɹÌÄ®Á¦Ç° ¹× ½Å¾àÀÇ ¿¬±¸, °³¹ß, »ý»ê ¹× ÆÇ¸Å
  • ´ëÇ¥ÀÚ±èÁö¾Ö
  • ¼³¸³ÀÏ1997³â 12¿ù 1ÀÏ
  • ¸ÅÃâ¾× 4¾ï 8,436¸¸¿ø (2025)
  • »ç¿ø¼ö-
  • Æò±Õ¿¬ºÀ1,708¸¸¿ø
  • ÀÚº»±Ý 63¾ï 8,867¸¸¿ø (ÇÑ½ÅÆòÁ¦°ø)

ȸ»ç¼Ò°³

¿¬Çõ

19971201 - ¼³¸³ : ÀÚº»±Ý 5,000¸¸¿ø
19980400 - Candida AlbicansÁø´Ü¿ë Žħ ¹× »ç¿ë¹æ¹ý ƯÇã Ãâ¿ø
19980600 - Aminoacyl-tRNA Synthease Ȱ¼ºÀ» ¾ïÁ¦ÇÏ´Â ¼¼Æ÷¼ºÀå¹°Áú ƯÇã
19980800 - ½Å±ÔÇ×»ý¹°Áú °Ë»ö KitƯÇã Ãâ¿ø
19980900 - 3,600¸¸¿ø ÁõÀÚ
19990100 - 5,050¸¸¿ø ÁõÀÚ
19990300 - Biotech Consulting Unit ½Å¼³,Homepage,Online BioMall°³¼³
19990400 - ½Å±Ô ¹Ù´Ò·ÎÀÌµå ¼ö¿ëüÀÇ °­·ÂÇÑ È¿¿ë¾à ¹× ÁøÅëÁ¦ ƯÇã Ãâ¿ø
19990400 - ¼º±Õ°ü´ëÇб³ â¾÷º¸À°¼¾ÅÍ ÀÔÁÖ
19990500 - Peptide°è Ç×¾ÏÁ¦Æ¯Çã Ãâ¿ø,¿ì¼öº¥Ã³±â¾÷ ÀÎÁõ(Áß¼Ò±â¾÷û)
19990600 - ÀÚü ÃâÀÚ±Ý 2¾ï2õ5¹é5½Ê¸¸¿øÀ» Á¶¼ºÇÏ¿© ÁõÀÚ
19990800 - Çѹ̾àǰ¢ßÀÌ 10¾ï¿øÀ» Equity Investment
19990900 - ¼º±Õ°ü´ë ³» À̸ÅÁø ±â¾÷ºÎ¼³¿¬±¸¼Ò °³¼³
19991100 - Ç×»ý¹°Áú °Ë»ö kit ƯÇã µî·Ï
19991200 - ¼º´ë ¿¬±¸¼Ò ³» ImaGene Áß¾Ó ¿¬±¸¼Ò °³¼³
20000300 - ¾×¸éºÐÇÒ ½Ç½Ã(1ÁÖ´ç ±Ý¾×5,000¿ø¿¡¼­ 500¿øÀ¸·Î º¯°æ)
20001200 - Á¦2ȸ â¾÷º¸À°¼¾ÅÍ ÀÔÁÖ±â°æ¿¬´ëȸ 'Àå·Á»ó¼ö»ó)
20010700 - ÀÚº»±Ý 3,400,000õ¿øÀ¸·Î ÁõÀÚ
20010900 - º¥Ã³±â¾÷ ÀçÁöÁ¤
20020900 - º»Á¡ ¹×ºÎ¼³¿¬±¸¼Ò ÅëÇÕÀÌÀü ¿Ï·á(¼­¿ï´ëÇб³ ³»)
20020924 - (ÁÖ)Ä͹ÙÀÌ¿À³Ø½º¸¦ Èí¼öÇÕº´ °áÀÇ
20030100 - ÇÕº´µî±â(ÁÖ½Äȸ»çÄ͹ÙÀÌ¿À³Ø½ºÈí¼öÇÕº´,Á¸¼Óȸ»ç´Â´ç»ç)
20031031 - ÀÚº»°¨¼Ò(ÀÚº»±Ý 4.15¾ï¿ø)
20031031 - À¯»óÁõÀÚ ÀÌ»çȸ °áÈñ
20031110 - ÀÌ»çȸ°áÀÇ (ÀÚº»°¨¼Ò.»óÈ£º¯°æ,ÀÓ¿ø¼±ÀÓ°Ç)
20050602 - °æ¹æ °è¿­È¸»ç¿¡ ÆíÀÔ
20050900 - """¿Á»çÁ¹¸®µò¿Â À¯µµÃ¼, ÀÌÀÇ Á¦Á¶¹æ¹ý, ¹× À̸¦ Æ÷ÇÔÇÏ´Â
20050900 - Á¶¼º¹°"" ±¹³»Æ¯Çã Ãëµæ"
20051000 - """Ç×»ýȰ¼ºÀ» °®´Â ½Å±ÔÇÑ ¾Æ¹Ì³ë¾Æ½Ç ¾Æµ¥´Ò·¹ÀÌÆ® À¯»çü
20051000 - ¹× ÀÌ È­ÇÕ¹°À» ÇÔÀ¯ÇÏ´Â ¾àÇÐÁ¶¼º¹°"" ±¹³» ƯÇã"
20060200 - ±¤ÇÐÀûÀ¸·Î Ȱ¼ºÀÎ ÇüÅÂÀÇ ¾ÆÁö¸®µò-2-Ä«¸£º¹½Ç»ê À¯µµÃ¼ ¹×
20060200 - ±×ÀÇ Á¦Á¶ ¹æ¹ý ±¹³» ƯÇã Ãëµæ
20060300 - ±¤ÇÐÀûÀ¸·Î Ȱ¼ºÀÎ 5,6-µð¿Á¼ÒÇÇÆä¶óÁø-2-Ä«¸£º¹½Ç»êÀ¯µµÃ¼ÀÇ
20060300 - Á¦Á¶¹æ¹ý ±¹³» ƯÇã Ãëµæ
20060500 - METHOD OF INDUCING PRODUCTION OF IL-8 OR TNF BY IN VITRO
20060500 - ADMINISTRATION OF AN N-TERMINAL POLYPEPTIDE
20060900 - Immunological enhancement agent comprising N-terminal
20060900 - peptide of p43 as an effective component ÀϺ»
20070102 - ÁÖ)¿ì¸®È¨¼îÇÎ ÁÖ½Ä 122,000ÁÖÀ» Àü·®¸Å°¢ & ´ë±Ý ÀϽðáÁ¦
20070900 - Optically Active Aziridine-2-Carboxylate Derivatives and a
20070900 - Process for Preparing them ¹Ì±¹ ƯÇã µî
20140600 - (ÁÖ)À̸ÅÁø ¼­¿ïÁöÁ¡ ¼³Ä¡(¼­¿ï ¿µµîÆ÷±¸ ¾çÆòµ¿)
20220300 - (ÁÖ)À̸ÅÁø ¼­¿ïÁöÁ¡ ÀÌÀü(¼­¿ï ¿µµîÆ÷±¸ ¿µµîÆ÷µ¿)

À繫ÇöȲ

ÀÚº»ÃѰè¸ÅÃâ¾×¼øÀÌÀͰá»êÀÏ
190¾ï 9,887¸¸¿ø 0¸¸¿ø- 2¾ï 429¸¸¿ø2017.12.31

´ÜÀ§: ¹é¸¸¿ø

°á»ê ³âµµÀÚº»ÃѰè¸ÅÃâ¾×¼øÀÌÀÍ
2017 190¾ï 9,887¸¸¿ø ¡é 0¸¸¿ø - 2¾ï 429¸¸¿ø ¡è
2016 201¾ï 1,627¸¸¿ø ¡é 0¸¸¿ø ¡é- 5¾ï 2,265¸¸¿ø ¡é
2015 233¾ï 8,885¸¸¿ø 4¾ï 8,436¸¸¿ø 9¾ï 3,422¸¸¿ø

Á¤º¸Á¦°ø: ³ªÀ̽ºµð¿£ºñ

1°³ÀÇ °è¿­»ç°¡ ÇÔ²²ÇÕ´Ï´Ù.

±â¾÷À§Ä¡

  • ÁÖ¼Ò : °æ±âµµ Æ÷õ½Ã °¡»ê¸é ¸¶Àü3±æ 15 (¸¶Àü¸®)
  • ȨÆäÀÌÁö : http://www.imagene.co.kr